Dongkook Pharmaceutical announced on the 24th that it has successfully completed Phase 3 clinical trials for a three-month formulation of Lorellin Depot, a long-acting injectable treatment for prostate cancer containing leuprorelin.
The three-month formulation is based on Dongkook Pharmaceutical's microsphere technology. Lorellin Depot contains leuprorelin, which suppresses gonadotropin secretion to reduce blood testosterone and estrogen levels, thereby treating the disease. Beyond prostate cancer, it is also used to treat hormone-related conditions including endometriosis and precocious puberty.
Dongkook Pharmaceutical plans to complete the clinical trial report by year-end and proceed with regulatory approval sequentially, targeting a launch next year.
The domestic leuprorelin market is estimated at approximately 80 billion won. The global market stands at around 5 trillion won. The U.S. market exceeds 2.5 trillion won and is growing at approximately 9% annually.